ArticleDiabetes, obesity & metabolism2026
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsWe evaluated the risk of mental health disorders among glucagon-like peptide-1 receptor agonist (GLP1RA) users compared with users of dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors. MATERIALS AND
methodsWe conducted a nationwide, active-comparator new-user cohort study using the Korean claims database from 2012 to 2022. Patients aged ≥ 18 years who initiated GLP1RAs, SGLT2 inhibitors, or DPP4 inhibitors for type 2 diabetes were included. We compared the hazard ratios (HRs) and 95% confidence intervals (CIs) for depression, anxiety, sleep disorders, and suicide using the Cox proportional hazards models after propensity score matching.
resultsThe 18 825 GLP1RA users were matched with 623 750 SGLT2 inhibitor users, and 5762 GLP1RA users with 874 902 inhibitor users. Compared with DPP4 inhibitors, GLP1RAs were not associated with increased risks of depression (HR 1.00 [95% CI, 0.83-1.20]), anxiety (0.92 [0.77-1.08]), or sleep disorder (1.14 [0.97-1.33]). In contrast, compared with SGLT2 inhibitors, GLP1RA use was associated with higher risks of depression (1.20 [1.09-1.31]) and anxiety (1.09 [1.00-1.19]). Suicidality events were rare and not observed among GLP1RA users.
conclusionsInitiation of GLP1RAs was not associated with increased risk of mental health disorders compared with DPP4 inhibitors. Differences in the risk of depression and anxiety were observed compared with SGLT2 inhibitors. These findings suggest that psychiatric safety signals may vary by active comparator and provide real-world evidence on the psychiatric safety of GLP-1-based therapies. Further studies incorporating detailed clinical data and high-risk subgroups are needed to clarify underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.